Piper Sandler analyst Jason Bednar raised the firm’s price target on Novocure to $80 from $70 and keeps a Neutral rating on the shares following the recent LUNAR headline data and the company’s Q4 preannouncement. However, with the shares trading above the updated price target, the analyst believes there’s "excess optimism" following the LUNAR news.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NVCR:
- Biotech Alert: Searches spiking for these stocks today
- Novocure sees Q4 revenue $128M, consensus $129.14M
- Medicare paying 9% more for Novocure’s Optune system in 2023, says Piper
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Novocure downgraded to Equal Weight from Overweight at Wells Fargo